Biology of Blood and Marrow Transplantation
Volume 13, Issue 5 , Pages 594-600 , May 2007

Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma

Received 3 March 2006 ,Accepted 16 January 2007.

References 

  1. Aisenberg AC. Problems in Hodgkin’s disease management. Blood. 1999;93:761–779
  2. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. [see comments] J Clin Oncol. 1997;15:528–534
  3. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210–218
  4. Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. [see comments] Blood. 1994;83:1193–1199
  5. Nademanee A, O’Donnell MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: results in 85 patients with analysis of prognostic factors. Blood. 1995;85:1381–1390
  6. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89:801–813
  7. Stiff PJ, Unger J, Fisher RI, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Sothwest Oncology Group Phase II trial. Biol Blood Marrow Transplant. 2003;9:529–539
  8. Jones RJ, Paintadosi S, Mann RB, et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol. 1990;8:527–537
  9. Lazarus HM, Loberiza FR, Zhang MJ, et al. Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from autologous blood and marrow transplant registry. Bone Marrow Transplant. 2001;27:387–396
  10. Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin’s disease and non-Hodgkin’s lymphoma: a dose-finding study. J Clin Oncol. 1990;8:648–656
  11. Reece DE, Nevill TJ, Sayegh A, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease. Bone Marrow Transplant. 1999;23:1131–1138
  12. Russell JA, Selby PJ, Ruether BA, et al. Treatment of advanced Hodgkin’s disease with high dose melphalan and autologous bone marrow transplantation. Bone Marrow Transplant. 1989;4:425–429
  13. Ahmed T, Lake DE, Beer M, et al. Single and double autotransplants for relapsing/refractory Hodgkin’s disease: results of two consecutive trials. Bone Marrow Transplant. 1997;19:449–454
  14. Brice P, Divine M, simon D, et al. SFGM/GELA Study Group Feasibility of tandem autologous stem-cell transplantation in induction failure or very unfavorable relapse from Hodgkin disease. Ann Oncol. 1999;10:1485–1488
  15. Brice P, Bouabdallah R, Stamatoullas A, et al. Single or tandem autologous stem cell trasnplantation according to prognostic factors at first Hodgkin lymphoma progression/relapse. Leuk Lymphoma. 2001;42(suppl 2):72
  16. Tarella C, Cuttica A, Vitolo , et al. High dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer. 2003;97:2748–2759
  17. Josting A, Rudolph C, Mapara M, et al. Cologone high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin lymphoma study Group. Ann Oncol. 2005;16:116–123

PII: S1083-8791(07)00119-X

doi: 10.1016/j.bbmt.2007.01.072

Biology of Blood and Marrow Transplantation
Volume 13, Issue 5 , Pages 594-600 , May 2007

Article Tools

* Image Usage & Resolution